FY2027 Earnings Estimate for ENTA Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised its earnings estimate for Enanta Pharmaceuticals for FY2027 from ($1.44) to ($1.42) per share, while the consensus estimate stands at ($4.65) per share.
• Several brokerages have adjusted their price targets for Enanta, with Evercore ISI lowering its target to $12.00 and Jefferies raising theirs to $20.00.
• Enanta Pharmaceuticals reported a quarterly earnings result of ($0.85) per share, surpassing expectations, with revenue of $18.31 million for the quarter.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Investment analysts at Leerink Partnrs upped their FY2027 earnings per share estimates for Enanta Pharmaceuticals in a research report issued on Monday, September 29th. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology company will post earnings of ($1.42) per share for the year, up from their previous estimate of ($1.44). The consensus estimate for Enanta Pharmaceuticals' current full-year earnings is ($4.65) per share. Leerink Partnrs also issued estimates for Enanta Pharmaceuticals' FY2028 earnings at ($1.15) EPS.

A number of other brokerages have also recently commented on ENTA. Evercore ISI dropped their price target on Enanta Pharmaceuticals from $20.00 to $12.00 and set an "outperform" rating for the company in a research note on Monday, September 15th. JMP Securities increased their target price on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 12th. Jefferies Financial Group upgraded Enanta Pharmaceuticals from a "hold" rating to a "buy" rating and boosted their price target for the stock from $14.00 to $20.00 in a report on Wednesday. Westpark Capital upped their price objective on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Tuesday. Finally, Wall Street Zen raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday, June 22nd. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $20.83.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ:ENTA opened at $10.61 on Thursday. Enanta Pharmaceuticals has a one year low of $4.09 and a one year high of $15.34. The company has a market cap of $226.84 million, a price-to-earnings ratio of -2.46 and a beta of 0.88. The firm has a 50 day simple moving average of $8.25 and a 200 day simple moving average of $6.93.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts' consensus estimates of ($1.25) by $0.40. The company had revenue of $18.31 million for the quarter, compared to the consensus estimate of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Jane Street Group LLC boosted its stake in Enanta Pharmaceuticals by 34.1% during the fourth quarter. Jane Street Group LLC now owns 31,072 shares of the biotechnology company's stock worth $179,000 after acquiring an additional 7,896 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth about $66,000. Public Employees Retirement System of Ohio boosted its position in shares of Enanta Pharmaceuticals by 117.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 15,726 shares of the biotechnology company's stock worth $90,000 after purchasing an additional 8,501 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Enanta Pharmaceuticals by 47.6% in the 4th quarter. Wellington Management Group LLP now owns 51,298 shares of the biotechnology company's stock valued at $295,000 after buying an additional 16,547 shares during the period. Finally, GAMMA Investing LLC bought a new stake in Enanta Pharmaceuticals in the 1st quarter valued at about $40,000. Institutional investors and hedge funds own 94.99% of the company's stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.